文献速递类风湿关节炎

探索基线类风湿因子水平对类风湿关节炎患者TNF抑制剂保留率的影响:一项多中心回顾性研究

Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study.
PubMed 文献 · RMD Open · 2024-02-23

该多中心回顾性研究纳入638例类风湿关节炎患者的752次TNF抑制剂治疗,按基线类风湿因子水平以第三四分位数200 IU/mL为界分组。在未接受过生物制剂且类风湿因子≥200 IU/mL的患者中,经倾向性评分匹配后, certolizumab pegol(CZP)的保留率显著长于单克隆抗体(HR 2.3,95%CI 1.2-4.3)和依那西普(HR 2.8,95%CI 1.5-5.2);而类风湿因子<200 IU/mL组间无差异。

要点

  • 在未接受过生物制剂且基线类风湿因子≥200 IU/mL的类风湿关节炎患者中,经倾向性评分匹配后,CZP的保留率显著长于单克隆抗体和依那西普。
  • 在基线类风湿因子<200 IU/mL的患者中,CZP、单克隆抗体和依那西普三组间的保留率无显著差异。
  • 结果提示类风湿因子可能通过结合某些TNF抑制剂的Fc段影响其保留率。

核心结论

  • 在基线类风湿因子≥200 IU/mL的类风湿关节炎患者中,CZP的保留率长于单克隆抗体和依那西普;而在<200 IU/mL的患者中无此差异。
  • 结果提示类风湿因子可能通过结合某些TNF抑制剂的Fc段产生潜在影响。

研究设计与样本

  • 多中心、纵向、回顾性研究,纳入接受任何TNF抑制剂(单克隆抗体、依那西普或CZP)治疗的类风湿关节炎患者。
  • 共纳入638例个体和752次治疗(132次CZP、439次单克隆抗体、181次依那西普)。
  • 按基线类风湿因子水平以第三四分位数200 IU/mL为界分为<200(<Q3)和≥200(≥Q3)IU/mL两组。
  • 采用Log-rank检验和Cox回归评估三组间的保留率。
  • 基于年龄、甲氨蝶呤联用和既往靶向合成/生物改善病情抗风湿药使用进行倾向性评分匹配的敏感性分析。

主要发现

  • 在未接受过生物制剂且类风湿因子≥200 IU/mL的患者中,CZP的保留率显著长于单克隆抗体和依那西普。
  • 经倾向性评分匹配后,类风湿因子≥200 IU/mL的患者中,CZP的保留率长于单克隆抗体(HR 2.3,95%CI 1.2-4.3)。
  • 经倾向性评分匹配后,类风湿因子≥200 IU/mL的患者中,CZP的保留率长于依那西普(HR 2.8,95%CI 1.5-5.2)。
  • 在类风湿因子<200 IU/mL的患者中,各组间未发现差异。

关键数值与推荐

  • 基线类风湿因子水平以第三四分位数200 IU/mL为界,分为<200(<Q3)和≥200(≥Q3)IU/mL。
  • 经倾向性评分匹配后,类风湿因子≥200 IU/mL组中CZP对比单克隆抗体的HR为2.3(95%CI 1.2-4.3)。
  • 经倾向性评分匹配后,类风湿因子≥200 IU/mL组中CZP对比依那西普的HR为2.8(95%CI 1.5-5.2)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. METHODS: Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cut-off: <200 (<Q3) and ≥200 (≥Q3) IU/mL. A sensitivity analysis matching patients using a propensity score technique based on age, concomitant use of methotrexate and previous targeted synthetic/biological disease-modifying antirheumatic drugs was performed to address the imbalance across groups. RESULTS: A total of 638 individuals and 752 treatments (132 CZP, 439 mAB and 181 ETA) were included. In non-naïve patients with ≥200 IU/mL of RF, those treated with CZP showed a significantly longer retention rate in comparison with mAB and ETA. After matching using the propensity score, patients with ≥200 IU/mL RF levels exhibited longer retention rates with CZP than with mAB (HR 2.3 (95% CI 1.2 to 4.3), or ETA (HR 2.8 (95% CI 1.5 to 5.2). No differences were found between groups in patients with <200 UI/mL. CONCLUSIONS: CZP showed a longer retention rate than mAB and ETA in patients with very high RF levels (≥200 IU/mL), while these differences were absent in patients with <200 IU/mL levels. The results suggest the potential effect of RF on binding the fragment crystallisable portion of certain TNFi.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. López-Medina C, Calvo-Gutiérrez J, Ábalos-Aguilera MC, et al. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open. 2024. PMID: 38395455. doi:10.1136/rmdopen-2023-003975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。